On 31 January 2008 Novo Nordisk initiated its share repurchase
programme in accordance with the provisions of the European
Commission's regulation no. 2273/2003 of 22 December 2003, also
referred to as the Safe Harbour rules.
Under the programme Novo Nordisk will repurchase B shares for an
amount of up to DKK 2 billion in the period from 31 January 2008 to 6
August 2008.
Since the announcement on 11 February 2008, the following
transactions have been made under the programme:
Number of Average Transaction
shares purchase price value, DKK
Accumulated, last 472,907 147,638,368
announcement
11 Feb 2008 50,000 324.4500 16,222,500
12 Feb 2008 50,000 328.6000 16,430,000
13 Feb 2008 50,000 327.9029 16,395,145
14 Feb 2008 50,000 331.7300 16,586,500
15 Feb 2008 50,000 331.4947 16,574,735
Accumulated, 2008 722,907 229,847,248
Transactions related to Novo Nordisk's incentive programmes have
resulted in a sale by Novo Nordisk of 232,445 B shares since last
announcement. The shares in these transactions were not part of the
Safe Harbour repurchase programme.
With the transactions stated above, Novo Nordisk owns a total of
25,692,260 treasury shares, corresponding to 4.0% of the share
capital. The total amount of shares in the company is 646,960,000
including treasury shares.
Novo Nordisk is a healthcare company and a world leader in diabetes
care. In addition, Novo Nordisk has a leading position within areas
such as haemostasis management, growth hormone therapy and hormone
replacement therapy. Novo Nordisk manufactures and markets
pharmaceutical products and services that make a significant
difference to patients, the medical profession and society. With
headquarters in Denmark, Novo Nordisk employs approximately 26,000
employees in 80 countries, and markets its products in 179 countries.
Novo Nordisk's B shares are listed on the stock exchanges in
Copenhagen and London. Its ADRs are listed on the New York Stock
Exchange under the symbol 'NVO'. For more information, visit
novonordisk.com.
Further information:
Media: Investors:
Outside North America: Outside North America:
Elin K Hansen Mads Veggerby Lausten
Tel: (+45) 4442 3450 Tel: (+45) 4443 7919
ekh@novonordisk.com mlau@novonordisk.com
Hans Rommer
Tel: (+45) 4442 4765
hrmm@novonordisk.com
In North America: In North America:
Sean Clements Christian Qvist Frandsen
Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937
secl@novonordisk.com cqfr@novonordisk.com
Stock Exchange Announcement no 10 / 2008